APAC - Epilepsy Therapeutic Market by Distribution Channel and Product - Forecast and Analysis 2024-2028

Published: Jan 2024 Pages: 156 SKU: IRTNTR44446

APAC - Epilepsy Therapeutic Market 2024-2028

The APAC - Epilepsy Therapeutic Market size is forecast to increase by USD 449.35 million, at a CAGR of 4.19% between 2023 and 2028.

There has been a rising awareness regarding epilepsy across the world. The increasing awareness is a major factor driving the market growth by increasing demand for effective AEDs for the management of epilepsy. In addition, the campaign aims at increasing awareness and education about epilepsy and enhancing the social acceptance of people with epilepsy. In addition, it also aims to encourage governments and other organizations to extend their support to epilepsy patients and to identify the needs and requirements of epilepsy patients. Hence, such factors are positively impacting the market.

Technavio has segmented the market into Distribution Channel and Product

  • The distribution channel segment is classified into hospital pharmacy, retail pharmacy, and online pharmacy
  • The product segment is classified into first-generation epilepsy therapeutics, second-generation epilepsy therapeutics, and third-generation epilepsy therapeutics

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the APAC Epilepsy Therapeutic Market During the Forecast Period?

To learn more about this report, Download Report Sample

APAC Epilepsy Therapeutic Market Segmentation by Distribution Channel and Product Analysis

Distribution Channel Analysis

Hospital pharmacy

The hospital pharmacy segment is estimated to witness significant growth during the forecast period. This segment offers a wide variety of AEDs and related pharmaceuticals to meet the specific needs of epilepsy patients. In addition, it involves the direct involvement of healthcare professionals, such as pharmacists and doctors, who are involved in the prescription and dispensing of medications based on patient needs.

Get a glance at the market contribution of various segments Download PDF Sample

The hospital pharmacy segment was the largest segment and was valued at USD 812.74 million in 2018. Moreover, one of the biggest advantages of using a hospital pharmacy for epilepsy therapeutics is that it integrates seamlessly with the rest of the healthcare system. Therefore, healthcare providers can work closely together to create customized treatment plans and adjust medication regimens as needed based on patient feedback. In addition, hospital pharmacies also often carry a wide variety of epilepsy medications. Furthermore, this allows patients to have a single point of contact for all their pharmaceutical needs. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Product Analysis

First-generation epilepsy therapeutics

The growth of this segment is fuelled by its established adoption among end-users owing to the first-mover advantage in the market. In addition, some of these drugs, such as Dilantin and Tegretol, exert their pharmacologic effect by blocking the voltage-dependent sodium channels. Moreover, these drugs are highly efficacious; however, most of them cause severe adverse effects, which has led to their decreased adoption among people in developed and developing countries. For example, Dilantin (phenytoin) causes a rash, ataxia, hirsutism, gingival hypertrophy, and osteoporosis. Hence, these factors under the first-generation epilepsy products segment will drive the growth of the epilepsy therapeutics market in APAC during the forecast period.

Second-generation epilepsy therapeutics

The second-generation AEDs comprises zonisamide, topiramate, gabapentin, pregabalin, felbamate, tiagabine, lamotrigine, and levetiracetam. In addition, the second-generation AEDs offer various advantages such as simpler pharmacokinetic profiles over the first-generation AEDs. Moreover, the market is growing due to the availability of drugs with better safety and tolerability profiles when compared with their predecessors, thus driving the demand for these drugs in APAC. In addition, the developed infrastructure in Japan and Australia, coupled with the presence of major players such as Eisai Co. Ltd., H Lundbeck AS, and UCB, is likely to further drive market growth by increasing the production and commercialization of second-generation AEDs in APAC. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Buy Full Report Now

Key APAC Epilepsy Therapeutic MarketPlayers 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 17 market companies, including:

Bausch Health Companies Inc: The company offers epilepsy therapeutics under the brand name Mysoline. 

  • Alkem Laboratories Ltd.
  • BIAL
  • Dr Reddys Laboratories Ltd.
  • Eisai Co. Ltd.
  • H Lundbeck AS
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SK Inc.
  • Sumitomo Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • GlaxoSmithKline Plc

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

APAC Epilepsy Therapeutic Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key APAC Epilepsy Therapeutic Market Drivers

One of the key factors driving the APAC epilepsy therapeutic market growth is the increase in the patient population having epilepsy.  There is an increasing prevalence of epilepsy with the annual incidence rate of epilepsy in developed countries is approximately 45-55 per 100,000 individuals, with higher rates in infants and older populations. In addition, in developing countries, the incidence rate is almost double, reaching about 95-105 per 100,000 individuals annually.

Moreover, the prevalence rate of epilepsy in developed countries is estimated between 5-10 per 1,000 individuals annually, whereas this rate is much higher in developing countries, reaching approximately 125-135 individuals annually.  Furthermore, developing countries witness high incidence and prevalence rates due to the increasing population and lack of proper diagnostic tools to refrain from detecting the early symptoms of epilepsy. In addition, the increase in the patient population is expected to increase the consumption of AEDs, thereby driving the growth of the APAC epilepsy therapeutics market during the forecast period.

Significant APAC Epilepsy Therapeutic Market Trends

A key factor shaping the APAC epilepsy therapeutic market growth is the reformation of marketed epilepsy drugs. Drug delivery systems including transdermal patches, extended-release (ER) formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing patient compliance or by increasing the bioavailability of the drug.  In addition, the reformulation of marketed drugs also provides an opportunity to grab patent term extensions, which can delay the entry of generic versions into the market.

Moreover, a single-loading dose was approved to provide an alternative to the standard titration schedule. Therefore, the reformulation of solid dosage forms such as tablets can provide a window for titrating the dose as per individual requirements.  Furthermore, ER formulations such as KEPPRA XR reduce the dosing frequency, thereby increasing patient compliance. Therefore, it is positively impacting the APAC - epilepsy therapeutic market. Hence, such factors are driving the APAC epilepsy therapeutic market growth during the forecast period.

Major APAC Epilepsy Therapeutic Market Challenges

The social stigma associated with mental disorders is one of the key challenges hindering the APAC epilepsy therapeutic market growth. Epilepsy and associated seizures are perceived variably in different parts of the world, resulting in dejection, isolation, and denial of education. In addition, in some parts of the world, including APAC, public disclosure of symptoms triggers negative reactions from family and friends, leading to seclusion. Furthermore, misconceptions about seizures and epilepsy can induce premature loss of self-dependence and identity in the affected person.

Moreover, seizures associated with epilepsy are perceived variably in different parts of the world, including APAC, ranging from a component of aging to a supernatural event. In addition, inaccurate assumptions regarding the cause of epilepsy lead to wrong interpretations about the impact of this disease on family members. Furthermore, the social stigma associated with these diseases can have an adverse impact on the social and personal lives of caregivers, including family members. Hence, such factors are hindering the APAC epilepsy therapeutic market growth during the forecast period.

Buy Now Full Report

Key APAC Epilepsy Therapeutic Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

APAC Epilepsy Therapeutic Market Customer Landscape

Segment Overview

The APAC epilepsy therapeutic market report forecasts market growth and provides a market growth analysis of the latest market trends and analysis and growth opportunities from 2018 to 2028. 

  • Distribution Channel Outlook
    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy
  • Product Outlook
    • First-generation epilepsy therapeutics
    • Second-generation epilepsy therapeutics
    • Third-generation epilepsy therapeutics

APAC Epilepsy Therapeutic Market Scope

Report Coverage

Details

Page number

156

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 4.19%

Market Growth 2024-2028

USD 449.35 million

Market structure

Fragmented

YoY growth 2023-2024(%)

3.77

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Alkem Laboratories Ltd., Bausch Health Companies Inc., BIAL, Dr Reddys Laboratories Ltd., Eisai Co. Ltd., H Lundbeck AS, Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, SK Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and GlaxoSmithKline Plc

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this APAC Epilepsy Therapeutic Market in Regional Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the APAC epilepsy therapeutic market between 2023 and 2028
  • Precise estimation of the APAC epilepsy therapeutic market size and its contribution to the market in focus on the parent market
  • Detailed market growth and forecasting analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate market forecast about upcoming market growth and trends and changes in consumer behavior
  • Growth of the market across APAC
  • A thorough market research and growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report of factors that will challenge the growth of the APAC epilepsy therapeutic market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Country Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on APAC - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on APAC: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Regional - Market size and forecast 2023-2028 ($ million)

    4 Historic Market Size

    • 4.1 epilepsy therapeutics market in APAC 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on epilepsy therapeutics market in APAC 2018 - 2022 ($ million)
    • 4.2 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 22: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 23: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 24: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 25: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 26: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 27: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 28: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 29: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 30: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 31: Chart on Comparison by Distribution Channel
      • Exhibit 32: Data Table on Comparison by Distribution Channel
    • 6.3 Hospital pharmacy - Market size and forecast 2023-2028
      • Exhibit 33: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 34: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
      • Exhibit 36: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
    • 6.4 Retail pharmacy - Market size and forecast 2023-2028
      • Exhibit 37: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 38: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
      • Exhibit 40: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
    • 6.5 Online pharmacy - Market size and forecast 2023-2028
      • Exhibit 41: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 42: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
      • Exhibit 44: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Distribution Channel
      • Exhibit 45: Market opportunity by Distribution Channel ($ million)
      • Exhibit 46: Data Table on Market opportunity by Distribution Channel ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 47: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 48: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 49: Chart on Comparison by Product
      • Exhibit 50: Data Table on Comparison by Product
    • 7.3 First-generation epilepsy therapeutics - Market size and forecast 2023-2028
      • Exhibit 51: Chart on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 52: Data Table on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 53: Chart on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
      • Exhibit 54: Data Table on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
    • 7.4 Second-generation epilepsy therapeutics - Market size and forecast 2023-2028
      • Exhibit 55: Chart on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 56: Data Table on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Chart on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
      • Exhibit 58: Data Table on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
    • 7.5 Third-generation epilepsy therapeutics - Market size and forecast 2023-2028
      • Exhibit 59: Chart on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 60: Data Table on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Chart on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
      • Exhibit 62: Data Table on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Product
      • Exhibit 63: Market opportunity by Product ($ million)
      • Exhibit 64: Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 65: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 66: Chart on Market share by geography - 2023-2028 (%)
      • Exhibit 67: Data Table on Market share by geography - 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 68: Chart on Geographic comparison
      • Exhibit 69: Data Table on Geographic comparison
    • 9.3 China - Market size and forecast 2023-2028
      • Exhibit 70: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 71: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 72: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 73: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.4 Japan - Market size and forecast 2023-2028
      • Exhibit 74: Chart on Japan - Market size and forecast 2023-2028 ($ million)
      • Exhibit 75: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 77: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.5 India - Market size and forecast 2023-2028
      • Exhibit 78: Chart on India - Market size and forecast 2023-2028 ($ million)
      • Exhibit 79: Data Table on India - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Chart on India - Year-over-year growth 2023-2028 (%)
      • Exhibit 81: Data Table on India - Year-over-year growth 2023-2028 (%)
    • 9.6 Australia - Market size and forecast 2023-2028
      • Exhibit 82: Chart on Australia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 83: Data Table on Australia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Chart on Australia - Year-over-year growth 2023-2028 (%)
      • Exhibit 85: Data Table on Australia - Year-over-year growth 2023-2028 (%)
    • 9.7 Rest of APAC - Market size and forecast 2023-2028
      • Exhibit 86: Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million)
      • Exhibit 87: Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Chart on Rest of APAC - Year-over-year growth 2023-2028 (%)
      • Exhibit 89: Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%)
    • 9.8 Market opportunity by geography
      • Exhibit 90: Market opportunity by geography ($ million)
      • Exhibit 91: Data Table on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 92: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 93: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 94: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 95: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 96: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 97: Matrix on vendor position and classification
            • 12.3 Bausch Health Companies Inc.
              • Exhibit 98: Bausch Health Companies Inc. - Overview
              • Exhibit 99: Bausch Health Companies Inc. - Business segments
              • Exhibit 100: Bausch Health Companies Inc. - Key news
              • Exhibit 101: Bausch Health Companies Inc. - Key offerings
              • Exhibit 102: Bausch Health Companies Inc. - Segment focus
            • 12.4 BIAL
              • Exhibit 103: BIAL - Overview
              • Exhibit 104: BIAL - Product / Service
              • Exhibit 105: BIAL - Key offerings
            • 12.5 Dr Reddys Laboratories Ltd.
              • Exhibit 106: Dr Reddys Laboratories Ltd. - Overview
              • Exhibit 107: Dr Reddys Laboratories Ltd. - Business segments
              • Exhibit 108: Dr Reddys Laboratories Ltd. - Key offerings
              • Exhibit 109: Dr Reddys Laboratories Ltd. - Segment focus
            • 12.6 Eisai Co. Ltd.
              • Exhibit 110: Eisai Co. Ltd. - Overview
              • Exhibit 111: Eisai Co. Ltd. - Business segments
              • Exhibit 112: Eisai Co. Ltd. - Key offerings
              • Exhibit 113: Eisai Co. Ltd. - Segment focus
            • 12.7 GlaxoSmithKline Plc
              • Exhibit 114: GlaxoSmithKline Plc - Overview
              • Exhibit 115: GlaxoSmithKline Plc - Business segments
              • Exhibit 116: GlaxoSmithKline Plc - Key news
              • Exhibit 117: GlaxoSmithKline Plc - Key offerings
              • Exhibit 118: GlaxoSmithKline Plc - Segment focus
            • 12.8 H Lundbeck AS
              • Exhibit 119: H Lundbeck AS - Overview
              • Exhibit 120: H Lundbeck AS - Product / Service
              • Exhibit 121: H Lundbeck AS - Key offerings
            • 12.9 Johnson and Johnson
              • Exhibit 122: Johnson and Johnson - Overview
              • Exhibit 123: Johnson and Johnson - Business segments
              • Exhibit 124: Johnson and Johnson - Key news
              • Exhibit 125: Johnson and Johnson - Key offerings
              • Exhibit 126: Johnson and Johnson - Segment focus
            • 12.10 Novartis AG
              • Exhibit 127: Novartis AG - Overview
              • Exhibit 128: Novartis AG - Business segments
              • Exhibit 129: Novartis AG - Key offerings
              • Exhibit 130: Novartis AG - Segment focus
            • 12.11 Pfizer Inc.
              • Exhibit 131: Pfizer Inc. - Overview
              • Exhibit 132: Pfizer Inc. - Product / Service
              • Exhibit 133: Pfizer Inc. - Key news
              • Exhibit 134: Pfizer Inc. - Key offerings
            • 12.12 Sanofi SA
              • Exhibit 135: Sanofi SA - Overview
              • Exhibit 136: Sanofi SA - Business segments
              • Exhibit 137: Sanofi SA - Key news
              • Exhibit 138: Sanofi SA - Key offerings
              • Exhibit 139: Sanofi SA - Segment focus
            • 12.13 SK Inc.
              • Exhibit 140: SK Inc. - Overview
              • Exhibit 141: SK Inc. - Product / Service
              • Exhibit 142: SK Inc. - Key offerings
            • 12.14 Sumitomo Pharma Co. Ltd.
              • Exhibit 143: Sumitomo Pharma Co. Ltd. - Overview
              • Exhibit 144: Sumitomo Pharma Co. Ltd. - Business segments
              • Exhibit 145: Sumitomo Pharma Co. Ltd. - Key offerings
              • Exhibit 146: Sumitomo Pharma Co. Ltd. - Segment focus
            • 12.15 Sun Pharmaceutical Industries Ltd.
              • Exhibit 147: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 148: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 149: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 150: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 151: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 152: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 153: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 154: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 UCB SA
              • Exhibit 155: UCB SA - Overview
              • Exhibit 156: UCB SA - Product / Service
              • Exhibit 157: UCB SA - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 158: Inclusions checklist
                • Exhibit 159: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 160: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 161: Research methodology
                • Exhibit 162: Validation techniques employed for market sizing
                • Exhibit 163: Information sources
              • 13.5 List of abbreviations
                • Exhibit 164: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              epilepsy therapeutic market in apac market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis